EGF and breast carcinoma: A recent study by Maiti et al. [37] demonstrated that a selective inhibitor of SphK2 (K-145) markedly attenuated epidermal growth factor (EGF)-mediated cell growth and survival of LM2-4 breast cancer cells, a cell line representative of the triple negative (progesterone/estrogen/herceptin 2 negative) breast cancers.